Imminent, page-24

There was a “Bio Shares” article (which can be viewed via the LBT website.)
The article suggests 4 potential sales to Germany, coupled with the First Australian sale. If this occurs and then a further 2 Australian sales are made at the 2 “other trial sites” then 5 sales for this year becomes 7. (I use the term if)
It also points out the LBT share of software revenue is high.
Acceptance of the technology and then subsequent sales in Europe coupled with a few locally, will improve investor sentiment. I would imagine a few trail sites in the U.S. prior to sales.
Just thinking out loud… but our friends in China that bought the Previlsola maybe keen to sell APAS once a sputum module is developed.
If we can get some runs on the board over the next 5 months coupled with the development of other modules then the share price will look after itself..